What Can GLP-1 Drugs Treat Besides Weight Loss?

Updated July 2026

GLP-1 medications started as diabetes drugs and became famous for weight loss. But the more researchers study them, the longer the list of conditions they seem to touch — some now backed by FDA approval, others that looked promising early and have since run into harder evidence. Here's an honest accounting of what these drugs can treat, and where the hype has outrun the proof. If you want the basics first, start with how GLP-1 drugs work.

What is GLP-1 approved to treat?

Quite a lot, and the list has grown fast. The first GLP-1 drug was approved for type 2 diabetes back in 2005, and the class remains highly effective at lowering blood sugar. Since then, these medications have earned FDA approval for obesity, for reducing heart attack and stroke risk in people with cardiovascular disease and excess weight, for moderate-to-severe obstructive sleep apnea, and for slowing kidney disease in people with type 2 diabetes. That's a remarkable range for one class of drug, and it hints at why GLP-1 receptors keep turning up in unexpected places.

Why does one drug help so many conditions?

Because much of the benefit flows downstream from weight loss itself. Obesity is a major driver of a long list of health problems, and GLP-1 drugs are very good at reducing weight — so anything that improves when weight comes down tends to improve on these medications. Sleep apnea and fatty liver disease are good examples: both can improve substantially with weight loss alone.

But not every benefit traces back to the scale. GLP-1 receptors aren't confined to the gut, pancreas, and brain — they sit throughout the body, which opens the door to effects that have nothing to do with weight.

How do GLP-1 drugs help the heart?

Through more than weight loss. GLP-1 receptors are found in the kidneys, where they help regulate blood pressure, and within atherosclerotic plaque, where stimulating them appears to calm inflammation and make plaque more stable. Lower blood pressure plus sturdier plaque adds up to fewer heart attacks and strokes, especially in people who already have heart disease and are therefore at highest risk. This is no longer theoretical: in 2024, based on the large SELECT trial, semaglutide (Wegovy) earned an FDA indication to reduce cardiovascular events in people with established heart disease and overweight or obesity. A GLP-1 drug is now, formally, a cardiovascular medication for that group.

Do GLP-1 drugs help with Alzheimer's or Parkinson's?

This is where early hope has collided with hard data. Because GLP-1 receptors exist in the brain and these drugs damp inflammation, researchers had real reason to think they might slow neurodegenerative disease, and encouraging early studies fueled the excitement. Then the definitive trials reported. In late 2025, two large phase 3 trials of semaglutide in early Alzheimer's did not slow disease progression, despite improving some biomarkers. And the largest, longest trial of a GLP-1 drug in Parkinson's showed no benefit on symptoms or brain imaging. The pattern was the same in both: promising in phase 2, neutral when tested rigorously. The door isn't shut — other formulations and earlier treatment windows are still being studied — but as of now, GLP-1 drugs are not a proven treatment for either disease.

Can GLP-1 drugs help joint pain?

Yes, at least for knee osteoarthritis tied to excess weight. A phase 3 trial reduced knee osteoarthritis pain in people with obesity, along with meaningful weight loss and better physical function. The likeliest explanation is straightforward — less weight means less load on the joints — which fits the broader theme that many of these benefits ride on weight loss. It isn't FDA-approved for arthritis, but the effect is real for the right patient.

Could GLP-1 drugs curb addiction?

Possibly, and this one is genuinely intriguing. The same brain signaling that dials down interest in food seems to dial down other compulsive urges too — early reports and small studies point to reduced drinking and even less compulsive gambling in some people. This is not a cure for alcohol-use disorder or addiction, and it isn't approved for either, but the signal is real enough that it's being actively studied as a possible tool.

The bottom line

GLP-1 medications are genuinely versatile, and for several conditions the evidence is now solid rather than speculative. But the neurodegenerative disappointments are a useful reminder: an appealing biological rationale is not the same as proof, and this class has real limits. Understanding those limits — including the downsides these drugs carry — matters as much as celebrating the wins. And for the many conditions that improve simply because weight improves, it's worth remembering that weight responds to what we eat, too.

If you're new to this site and found this useful, I write one of these evidence-based articles every week. You can get them in your inbox by joining my email list at the bottom of this page. No spam, no requirement to buy anything, just practical knowledge.